Chui MH - Search Results

1

Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.

Park Y, Chui MH, Suryo Rahmanto Y, Yu ZC, Shamanna RA, Bellani MA, Gaillard S, Ayhan A, Viswanathan A, Seidman MM, Franco S, Leung AKL, Bohr VA, Shih IM, Wang TL. Park Y, et al. Among authors: chui mh. Clin Cancer Res. 2019 Sep 15;25(18):5584-5594. doi: 10.1158/1078-0432.CCR-18-4222. Epub 2019 Jun 13. Clin Cancer Res. 2019. PMID: 31196855 Free PMC article.

2

Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.

Wu RC, Ayhan A, Maeda D, Kim KR, Clarke BA, Shaw P, Chui MH, Rosen B, Shih IeM, Wang TL. Wu RC, et al. Among authors: chui mh. J Pathol. 2014 Mar;232(4):473-81. doi: 10.1002/path.4315. J Pathol. 2014. PMID: 24338723 Free PMC article.

3

Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma.

Chui MH, Wang Y, Wu RC, Seidman J, Kurman RJ, Wang TL, Shih IeM. Chui MH, et al. Mod Pathol. 2015 Mar;28(3):437-45. doi: 10.1038/modpathol.2014.89. Epub 2014 Sep 12. Mod Pathol. 2015. PMID: 25216223 Free PMC article.

4

Endometriosis: benign, malignant, or something in between?

Chui MH, Wang TL, Shih IM. Chui MH, et al. Oncotarget. 2017 Sep 19;8(45):78263-78264. doi: 10.18632/oncotarget.21051. eCollection 2017 Oct 3. Oncotarget. 2017. PMID: 29108226 Free PMC article. No abstract available.

5

Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma.

Yen TT, Miyamoto T, Asaka S, Chui MH, Wang Y, Lin SF, Stone RL, Fader AN, Asaka R, Kashima H, Shiozawa T, Wang TL, Shih IM, Tanner EJ 3rd. Yen TT, et al. Among authors: chui mh. Gynecol Oncol. 2018 Sep;150(3):426-431. doi: 10.1016/j.ygyno.2018.06.025. Epub 2018 Jul 4. Gynecol Oncol. 2018. PMID: 30126589

6

Cytomorphologic and molecular analyses of fallopian tube fimbrial brushings for diagnosis of serous tubal intraepithelial carcinoma.

Chui MH, Vang R, Wang TL, Shih IM, VandenBussche CJ. Chui MH, et al. Cancer Cytopathol. 2019 Mar;127(3):192-201. doi: 10.1002/cncy.22110. Epub 2019 Mar 12. Cancer Cytopathol. 2019. PMID: 30861338 Free PMC article.

7

Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.

Chui MH, Xing D, Zeppernick F, Wang ZQ, Hannibal CG, Frederiksen K, Kjaer SK, Cope L, Kurman RJ, Shih IM, Wang TL, Vang R. Chui MH, et al. Am J Surg Pathol. 2019 Nov;43(11):1462-1472. doi: 10.1097/PAS.0000000000001325. Am J Surg Pathol. 2019. PMID: 31343420 Free PMC article.

8

Oncogenic BRAF and KRAS mutations in endosalpingiosis.

Chui MH, Shih IM. Chui MH, et al. J Pathol. 2020 Feb;250(2):148-158. doi: 10.1002/path.5353. Epub 2019 Nov 29. J Pathol. 2020. PMID: 31576556 Free PMC article.

9

BRAF^V600E -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma.

Chui MH, Kjaer SK, Frederiksen K, Hannibal CG, Wang TL, Vang R, Shih IM. Chui MH, et al. Oncotarget. 2019 Dec 3;10(64):6870-6878. doi: 10.18632/oncotarget.27326. eCollection 2019 Dec 3. Oncotarget. 2019. PMID: 31839880 Free PMC article.

10

Correction: BRAF^V600E -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma.

Chui MH, Kjaer SK, Frederiksen K, Hannibal CG, Wang TL, Vang R, Shih IM. Chui MH, et al. Oncotarget. 2021 Jun 22;12(13):1323-1324. doi: 10.18632/oncotarget.28001. eCollection 2021 Jun 22. Oncotarget. 2021. PMID: 34194631 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

57 results

Search Page

Filters